Drug Detail:Hyperrab (human) (Rabies immune globulin (human) (test))
Generic Name: Human Rabies Virus Immune Globulin 300[iU] in 1mL
Dosage Form: injection, solution
Drug Class: Immune globulins
For infiltration and intramuscular use only.
The strength of HYPERRAB is 300 IU/mL.
Dose
Use HYPERRAB in combination with rabies vaccine series to be effective. Do not use HYPERRAB alone for prevention.
Administer HYPERRAB within 7 days after the first dose of rabies vaccine.
| Vaccination Status | Treatment | Regimen† |
|
||
| Not previously vaccinated | Wound cleansing | • Cleanse all wounds immediately and thoroughly with soap and water. • Irrigate the wounds with a virucidal agent such as a povidone-iodine solution, if available. |
HYPERRAB 20 IU/kg body weight OR 0.0665 mL/kg body weight Single-dose |
• Administer HYPERRAB as soon as possible after exposure, preferably at the time of the first vaccine dose. • Infiltrate the full dose of HYPERRAB thoroughly in the area around and into the wound(s), if anatomically feasible. [see Dosage and Administration (2.3)] • Inject the remainder, if any, intramuscularly at an anatomical site distant from the site of vaccine administration. [see Dosage and Administration (2.3)] • Do not exceed the recommended dose of HYPERRAB, otherwise the active production of rabies antibody may be partially suppressed. [see Drug Interactions (7)] • Use separate syringes, needles, and anatomical injection sites for HYPERRAB and for rabies vaccine. |
|
| Rabies Vaccine | • Administer rabies vaccine on day 0‡ • Complete a rabies vaccination series for previously unvaccinated persons.† |
|
| Previously vaccinated§ | Wound cleansing | • Cleanse all wounds immediately and thoroughly with soap and water. • Irrigate the wounds with a virucidal agent such as a povidone-iodine solution, if available. |
| HYPERRAB | • Do not administer HYPERRAB. [see Indications and Usage (1)] | |
| Rabies Vaccine | • Administer rabies vaccine on day 0‡. • Complete a rabies vaccination series for previously vaccinated persons.† |
|
Preparation
- Calculate the volume of HYPERRAB for the recommended dose of 20 IU/kg.
- Ensure the correct strength is used for the calculation. HYPERRAB is formulated with a strength of 300 IU/mL. The predecessor product, HYPERRAB® S/D [rabies immune globulin (human)] was formulated at 150 IU/mL. The volume required of HYPERRAB (300 IU/mL) to achieve the recommended dose of 20 IU/kg is approximately one half of that required for the previous HYPERRAB S/D (150 IU/mL).
- Visually inspect parenteral drug products for particulate matter and discoloration prior to administration, whenever solution and container permit. HYPERRABis a clear or slightly opalescent, and colorless or pale yellow sterile solution.
- Do not use HYPERRAB if the product shows any sign of tampering. Notify Grifols Therapeutics LLC immediately [1-800-520-2807].
- Do not freeze. Do not use any solution that has been frozen.
- Discard unused portion.
Administration
- Administer HYPERRAB at the time of the first vaccine dose (day 0), but no later than day 7.(1-3)
- Infiltrate the full dose of HYPERRAB in the area around the wound, if anatomically feasible. Dilute HYPERRAB with an equal volume of dextrose, 5% (D5W), if additional volume is needed to infiltrate the entire wound. Do not dilute with normal saline.
- Inject the remainder, if any, of the HYPERRAB dose intramuscularly into the deltoid muscle of the upper arm or into the lateral thigh muscle, and distant from the site of vaccine administration.
- Do not administer HYPERRAB in the same syringe or needle or in the same anatomic site as vaccine.
